Pieris finally vaults FDA hold on next-gen solid tumor hunter, clearing the path for mid-stage trial

Nicole DeFeudis

Editor

Finally freed from the restraints of a partial FDA clinical hold on its lead HER2-positive solid tumor candidate, Pieris Pharmaceuticals is now racing toward Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pieris finally vaults FDA hold on next-gen solid tumor hunter, clearing the path for mid-stage trial

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pieris fi­nal­ly vaults FDA hold on next-gen sol­id tu­mor hunter, clear­ing the path for mid-stage tri­al

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pieris finally vaults FDA hold on next-gen solid tumor hunter, clearing the path for mid-stage trial